Adverum Biotechnologies to Present at Upcoming Conferences
September 28 2017 - 9:00AM
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy
company advancing novel medicines to address unmet needs in serious
rare and ocular diseases, announced today that company executives
will present at upcoming conferences in October.
Event: |
|
|
Cell & Gene Meeting
on the Mesa |
Date: |
|
|
October
5, 2017 |
Time: |
|
|
2:15 – 2:30 p.m.
PT |
Location: |
|
|
La Jolla, CA |
Presentation: |
|
|
Amber Salzman, Ph.D.,
president and chief executive officer |
|
|
|
|
Event: |
|
|
Chardan Gene Therapy
Conference |
Date: |
|
|
October
10, 2017 |
Time: |
|
|
2:00 – 2:25 p.m.
ET |
Location: |
|
|
New York, NY |
Presentation: |
|
|
Amber Salzman, Ph.D.,
president and chief executive officer |
|
|
|
|
Event: |
|
|
Jefferies Gene
Technology Summit Conference |
Date: |
|
|
October
12, 2017 |
Location: |
|
|
New York, NY |
Panel: |
|
|
Mehdi Gasmi, Ph.D.,
chief science and technology officer |
A live and replay video webcast of the Cell & Gene Meeting
on the Mesa may be accessed by visiting
www.meetingonthemesa.com/webcast/.
A live and replay audio webcast of the Chardan Gene Therapy
Conference fireside chat will be available from Adverum’s website
at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.Adverum is a
gene therapy company advancing novel medicines that may offer
life-changing benefits to patients living with serious rare and
ocular diseases. Adverum has a robust pipeline that includes
product candidates designed to treat rare diseases alpha-1
antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as
well as wet age-related macular degeneration (wAMD). Leveraging a
next-generation adeno-associated virus (AAV)-based directed
evolution platform, the Company generates product candidates
designed to provide durable efficacy by inducing sustained
expression of a therapeutic protein. Adverum has collaboration
agreements with Regeneron Pharmaceuticals to research, develop, and
commercialize gene therapy products for ophthalmic diseases and
Editas Medicine to explore the delivery of genome editing medicines
for the treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development and in-house
manufacturing expertise, specifically in process development and
assay development. For more information please visit
www.adverum.com.
Adverum Contact:
Charles Butler
Vice President, Investor Relations &
Corporate Communications
650-272-6260
cbutler@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024